Michael Wismer, MD
Hematology & Oncology · Meadville, PANPI 1265960702
Payments from drug & device makers
Across 33 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$84
- Incyte Corporation$83
- Novartis$59
- Array Biopharma Inc$57
- Genentech USA, Inc.$54
- Merck$49
- plus $291 from 11 others
What the payments were for
- Food & beverage$677100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 4 | $84 |
| Incyte Corporation | 4 | $83 |
| Novartis | 3 | $59 |
| Array Biopharma Inc | 3 | $57 |
| Genentech USA, Inc. | 2 | $54 |
| Merck | 3 | $49 |
| Sanofi | 3 | $48 |
| Astellas Pharma US Inc | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 1 | $34 |
| AbbVie | 1 | $25 |
| Bristol Myers Squibb | 1 | $24 |
| Lilly USA, LLC | 1 | $24 |
| Pharmaessentia USA Corporation | 1 | $22 |
| Pfizer | 1 | $21 |
| Tempus AI, Inc | 1 | $18 |
| Gilead | 1 | $17 |
| Stemline Therapeutics Inc. | 1 | $16 |
How this compares
$677 in reported general payments places this provider in the 25th percentile of 682 hematology & oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Imatinib Mesylate | 11 | $37,685 |
| Dexamethasone | 24 | $197 |
| Acyclovir | 13 | $50 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Meadville
- Diwakar DavarPittsburgh$21.6M
- Jason LukePittsburgh$15M
- Stephen BagleyPhiladelphia$13.1M
- Leonard ApplemanPittsburgh$12.8M
- Jing Zhou HouPittsburgh$11.9M
- Taofeek OwonikokoPittsburgh$9.7M
- Stephen SchusterPhiladelphia$9.5M
- Pooja GhataliaPhiladelphia$8.3M
- Corey LangerPhiladelphia$7.7M
- Alfred GarfallPhiladelphia$7.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.